Amifostine (wr2721) confers dna protection to in vivo cisplatin-treated murine peripheral blood leukocytes

Dose-Response

Volumn 7, Issue 3, 2009, Pages 234-246

  González, E A Prieto ^a   Fuchs, A G ^a   Sánchez, González S ^b  

^a UNIVERSIDAD ABIERTA INTERAMERICANA   (Argentina)

^b UNIVERSIDAD DE CIENCIAS MÉDICAS DE LA HABANA   (Cuba)

Author keywords

Amifostine; Antioxidant; Cisplatin; Comet assay; DNA damage; Lymphocytes

Indexed keywords

EID: 70349747142     PISSN: None     EISSN: 15593258     Source Type: Journal    
DOI: 10.2203/dose-response.08-026.prieto     Document Type: Article

References (63)

1. Aebi H. 1984. Catalase in vitro. Methods Enzimol.105: 121-126
2. Anderson D, Yu TW, Phillips BJ, Scheneider P. 1994. The effect of various antioxidants and other modifying agents on oxygen radicals generated DNA damage in human lymphocytes in the comet assay. Mutat Res. 307: 261-271
3. Atalay H, Aybek H, Koseoglu M, Demir S, Erbay H, Bolaman AZ, Avci A. 2006. The effects of amifos-tine and dexamethasone on brain tissue lipid peroxidation during oxygen treatment of carbon monoxide-poisoned rats. Adv Ther. 2: 332-341
4. Bergström P, Johnsson A, Bergenheim T, Henriksson R., 1999. Effects of amifostine on cisplatin induced DNA adduct formation and toxicity in malignant glioma and normal tissues in rat. J. Neurooncol. Mar, 1: 13-21
5. Bhattacharya R, PV Lakshmana Rao, SC. Pant, P Kumar, R. K. Tulsawani, U. Pathak, A. Kulkarni, and Vijayaraghavan R. 2001. Protective Effects of Amifostine and Its Analogues on Sulfur Mustard Toxicity in Vitro and in Vivo Toxicol and Applied Pharmacol. 176: 24-33
6. Blasiak J, Gloc E, Wozniak K, Mlynarski W, Stolarska M, Skorski T and Majsterek I. 2002. Genotoxicity of idarubicin and its modulation by vitamins C and E and amifostine. Chem Biol Interact. 140: 1-18
7. Bolaman Z, Cicek C, Kadikoylu G, Barutca S, Serter M, Yenisey C and Alper G. 2005. The protective effects of amifostine on adriamycin-induced acute cardiotoxicity in rats. Tohoku J Exp Med. 207: 249-253
8. Boulikas T, Vougiouka M. 2003. Cisplatin and platinum drugs at the molecular level. (Review). Oncol Rep. 10:1663-1682
9. Brenner B, Wasserman L, Beery E, Nordenberg J, Schechter J, Gutman H and Fenig E. 2003. Variable cytotoxicity of amifostine in malignant and nonmalignant cell lines. Oncol Rep. 10: 1609-1613
10. Brenner W, Uwe Kampen W, von Forstner C, Brümmer C, Zuhayra M, Muhle C, Czech N, Henze H.. 2001. High-Dose Treatment with 186Re-HEDP or 153Sm-EDTMP Combined with Amifostine in a Rabbit Model. Journal of Nuclear Medicine 42: 1545-1550
11. Buschini A, Anceschi E, Carlo-Stella C, Regazzi E, Rizzoli V, Poli P and Rossi C.2000. Amifostine (WR-2721) selective protection against melphalan genotoxicity. Leukemia. 12: 1642-1651
12. Campos Nebel M, Larripa I, Gonzalez-Cid M. 2002. Differential antigenotoxic and cytoprotective effect of amifostine in idarubicin-treated mice. Environ Mol Mutagen. 39: 3-9
13. Church MW, Blakley BW, Burgio DL and Gupta A. K. 2004. WR-2721 (Amifostine) Ameliorates Cisplatin-Induced Hearing Loss But Causes Neurotoxicity In Hamsters: Dose-Dependent Effects. JARO. 226: 227-237
14. Duez P, Dehon G, Kumps A and Dubois J. 2003. Statistics of the Comet assay: a key to discriminate between genotoxic effects. Mutagenesis. 18: 159-166
15. Ferrer M, Izeboud T, Ferreira CG, Span SW, Giaccone G and Kruyt FA.2003. Cisplatin triggers apop-totic or nonapoptotic cell death in Fanconi anemia lymphoblasts in a concentration-dependent manner. Exp Cell Res. 286: 381-395
16. Giannopoulou E and Papadimitriou E. 2003. Amifostine has Antiangiogenic Properties In Vitro by Changing the Redox Status of Human Endothelial Cells. Free Radic Res. 37: 1191-1199
17. Gloc E., M. Warszawski, W. Mynarski, M. Stolarska, G. Hoser, T Skorski. and Basiak J. 2002. TEL/JAK2 tyrosine kinase inhibits DNA repair in the presence of amifostine. Acta Biochim Pol. 49: 121-128
18. Goodisman J, Hagrman D, Tacka KA and Souid AK.2006. Analysis of cytotoxicities of platinum compounds.. Cancer Chemother Pharmacol. 57: 257-267
19. Grdina DJ, Kataoka Y, and Murley JS.2000. Amifostine: mechanisms of action underlying cytoprotec-tion and chemoprevention. Drug Metab Drug Interact 16: 237-279
20. Hospers, GA Eisenhauer EA and de Vries EG. 1999. The sulphydryl container compounds WR 2721 and glutathione as radio-and chemoprotective agents A. review, indications for use and prospects. Br. J. Cancer. 80: 629-638
21. Jänicke RU Sohn D and Schulze-Osthoff K. 2008. The dark side of a tumor suppressor: anti-apoptot-ic p53. Cell Death Differ. 15: 959-76
22. Jatoi A, Martenson JA, Mahoney MR, Lair BS, Brindle JS, Nichols F, Caron N, Rowland K, Tschetter L and Alberts S. 2004. Results of a planned interim toxicity analysis with trimodality therapy, including carboplatin AUC = 4, paclitaxel, 5-fluorouracil, amifostine, and radiation for locally advanced esophageal cancer: preliminary analyses and treatment recommendations from the North Central Cancer Treatment Group. Int Semin Surg Oncol. 1:1-9
23. Khodarev NN, Kataoka Y, Murley JS, Weichselbaum RR Grdina DJ. 2004. Interaction of amifos-tine and ionizing radiation on transcriptional patterns of apoptotic genes expressed in human microvascular endothelial cells (HMEC). Int J Radiat Oncol Biol Phys. 60: 553-563
24. Klutmann S, Bohuslavizki KH, Kröger S, et al. 2000. A rabbit animal model to evaluate myeloprotec-tive effects of amifostine in palliation therapy with Re-186-HEDP [abstract]. Nuklearmedizin. 39:A89.
25. Kollmannsberger C, Kuzcyk M, Mayer F, Hartmann JT, Kanz L and Bokemeyer C.1999. Late toxicity following curative treatment of testicular cancer. Surg. Oncol. 17: 275-281
26. Koukourakis M I. 2002. Amifostine in clinical oncology: current use and future applications Anticancer Drugs. 13: 181-209
27. Kouloulias VE, Kouvaris JR, Pissakas G, Mallas E, Antypas C, Kokakis JD, Matsopoulos G, Michopoulos S, Mystakidou K and Vlahos L. J. 2005. Phase II multicenter randomized study of amifostine for prevention of acute radiation rectal toxicity: topical intrarectal versus subcutaneous application. Int J Radiat Oncol Biol Phys. 62: 486-493
28. Kouvaris J R, Koulouris V. E. and Vlahos J. 2007. Amifostine: The First Selective-Target and Broad-Spectrum Radioprotector Oncologist. 12:738 - 747
29. Lee EJ, Gerhold M, Palmer MW and Christen RD.2003. p53 protein regulates the effects of amifos-tine on apoptosis, cell cycle progression, and cytoprotection. Br J Cancer. 5: 754-759
30. Lieder B, Pluim D, Schellens J, Thomale J. 2006. Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei. Nucleic Acids Res. e34-e47
31. Littlefield LG, Hoffmann GR.1993. Modulation of the clastogenic activity of ionizing radiation and bleomycin by the aminothiol WR-1065. Environ. Mol. Mutagen. 22: 225-230
32. Majsterek I, Gloc E, Blasiak J and Reiter R J. 2005. A comparison of the action of amifostine and mela-tonin on DNA damaging effects and apoptosis induced by idarubicin in normal and cancer cells. J Pineal Res. 38: 254-263
33. Mantovani G, Macciò A, Madeddu C, Mura L, Massa E, Gramignano G, Lusso MR, Murgia V, Camboni P and Ferreli L. 2003. Reactive oxygen species, antioxidant mechanisms, and serum cytokine levels in cancer patients: impact of an antioxidant treatment. J Environ Pathol Toxicol Oncol. 22: 17-28
34. Marzatico F, Porta C, Moroni M, Bertorelli L, Borasio E, Finotti N, Pansarasa O and Castagna L. 2000. In vitro antioxidant properties of amifostine (WR-2721, Ethyol). Cancer Chemother Pharmacol. 45: 172-176
35. Mazur L and Czyzewska A.1994. Inhibition of the clastogenic effect of cyclophosphamide by WR-2721 in the bone marrow of mice. Mutat Res. 309: 219-223
36. Mertsch K, Grune, Kunstmann S, Wiesner B, Ladhoff AM, Siems WG, Haseloff RF and Blasig I. E. 1998. Protective effects of the thiophosphate amifostine (WR 2721) and a lazaroid (U83836E) on lipid peroxidation in endothelial cell during hypoxial reoxygenation. Biochem. Pharmacol. 56: 945-954
37. Muller AC, Pigorsch S, Beyer C, Lautenschlager C and Dunst J.2004. Radioprotective effects of ami-fostine in vitro and in vivo measured with the comet assay. Strahlenther Onkol.180: 517-525
38. Murley JS, Kataoka Y, Dingca JC, Jian JL, Oberley LW Grdina DJ. 2004. Delayed radioprotection by NF-B-mediated induction of Sod2 (MnSOD) in SA-NH tumor cells after exposure to clinically used thiol-containing drugs. Radiation res. 162: 536-546
39. Nadin SB, Vargas-Roig LM, Drago G, Ibarra J Ciocca DR. 2006. DNA damage and repair in peripheral blood lymphocytes from healthy individuals and cancer patients: A pilot study on the implications in the clinical response to chemotherapy. Cancer Lett. 252: 84-97
40. Ortiz LA, Lasky JA, Safah H, Reyes M, Miller A, Lungarella G and Friedman M.1999. Exacerbation of bleomycin-induced lung injury in mice by amifostine. Am J Physiol Lung Cell Mol Physiol. 277: 1239-1244
41. Perret C, Foultier MT, Vonarx-Coinsman V, Quancard O, Combre A and Patrice T. 1994. Malondialdehyde dosimetry in laser-irradiated tissues sensitized by hematoporphyrin derivative. J Pharmacol Exp Ther. 269: 787-791
42. Pierelli L, Scambia G, Fattorossi A, Bonanno G, Battaglia A, Perillo A, Menichella G, Panici PB, Leone G and Mancuso S.1998. In vitro effect of amifostine on haematopoietic progenitors exposed to carboplatin and nonalkylating antineoplastic drugs: aematoprotection acts as a drug-specific progenitor rescue. Br. J. Cancer. 78: 1024-1029
43. Provinciali M, Ciavattini A, Di Stefano G, Argentati K and Garzetti GG.1999. In vivo amifostine (WR 2721) prevents chemotherapy-induced apoptosis of peripheralblood lymphocytes from cancer patients. Life Sci. 64: 1525-1532
44. Reinhardt-Poulin P, McLean JR, Deslauriers Y, Gorman W, Cabat S and Rouabhia M. 2000. The use of silver-stained "comets" to visualize DNA damage and repair in normal and xeroderma pig-mentosum fibroblasts. Photochem Photobiol. 71: 422-425
45. Ries LAG, Harkins D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Eisner MP, Horner MJ, Howlader N, Hayat M, Hankey BF, Edwards BK (eds), 2006. SEER Cancer Statistics Review, 1975-2003, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975-2003
46. Sadowitz, PD, Hubbard BA, Dabrowiak JC, Goodisman J, Tacka KA, Aktas M. K., Cunningham MJ, Dubowy RL and Souid A. K.2002. Kinetics of Cisplatin Binding to Cellular DNA and Modulations by Thiol-Blocking Agents and Thiol Drugs. Drug Metab. Dispos. 30: 183-190
47. Sancar A. 1994. Mechanisms of DNA excision repair Science. 266:1954 - 1956
48. Santini V. 2001. Amifostine: chemotherapeutic and radiotherapeutic protective effects. Expert Opin Pharmacother. 2: 479-489
49. Schor NF.1988. Mechanism of synergistic toxicity of the radioprotective agent (WR2722) and 6-hydroxydopamine. Biochemical Pharmacology 2: 1751-1762.
50. Singh NP, McCoy MT, Tice RR and Schneider EL.1988. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res. 175: 184-191
51. Siomek A, Tujakowski J, Gackowski D, Rozalski R, Foksinski M, Dziaman T, Roszkowski K and Olinski R. 2006. Severe oxidatively damaged DNA after cisplatin treatment of cancer patients. Int J Cancer. 119: 2228-2230
52. Spitz, DR and Oberley, LW. 1989. An assay for superoxide dismutase activity in mammalian tissue homogenates. Anal Biochem 179: 8-18
53. Stankiewicz A and Skrzydlewska E. 2003. Protection Against Cyclophosphamide- Induced Renal Oxidative Stress by Amifostine: The Role of Antioxidative Mechanisms. Toxicol. Mech. Methods. 13:301-308
54. Stankiewicz A, Skrzydlewska E, Makiea M. 2002. Effects of amifostine on liver oxidative stress caused by cyclophosphamide administration to rats. Drug Metabol Drug Interact. 19: 67-82.
55. Tabachnik Schor NF. 1987. Adjunctive use of Ethiofos (WR2722) with free radicals-generating chemotherapeutic agents in mice: New caveats for therapy. Cancer Research 47: 5411-5414.
56. Tice RR, Agurell E, Anderson D, Burlinson B, Hartmann A, Kobayashi H, Miyamae Y, Rojas E, Ryu J.-C and Sasaki Y F. 2000. Single Cell Gel/Comet Assay: Guidelines for In Vitro and In Vivo Genetic Toxicology Testing. Environ Mol Mutagen. 35: 206-221
57. Tice RR. 1995. The single cell gel/comet assay: a microgel electrophoretic technique for the detection of DNA damage and repair individual cells, in: DH. Phillips, S. Venitt (eds.), Environmental Mutagenesis; Bios Scientific Publishers LTD, Oxford, UK, 315-339.
58. Vellon L, M Gonzalez Cid, MD Nebel, Larripa I. 2005. Additive apoptotic effect of STI571 with the cytoprotective agent amifostine in K-562 cell line. Cancer Chemother Pharmacol 55: 602-608
59. Wills BK, Aks S, Maloney GE, Rhee J, Brand R and Sekosan M. 2007. The effect of amifostine, a cyto-protective agent on paraquat toxicity in mice. J Med Toxicol. 3: 1-6
60. Wozniak K, Czechowska A, Blasiak J. 2004. Cisplatin-evoked DNA fragmentation in normal and cancer cells and its modulation by free radical scavengers and the tyrosine kinase inhibitor STI571. Chem Biol Interact, 147: 309-318
61. Xunclà M, Barquinero JF, Caballín MR, Craven-Bartle J, Ribas M, de Vega JM and Barrios L. 2008. Cytogenetic damage induced by radiotherapy. Evaluation of protection by amifostine and analysis of chromosome aberrations persistence. Int J Radiat Biol.84: 243-251
62. Yagi K. 1984. Assay for blood plasma or serum. Methods Enzymol. 105: 328-331
63. Yuhas JM. 1980. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino ethiylphosphorotioic acid. Cancer Res. 40: 1519-1524